Skip to main content

Raising Capital and the IPO Process

Cohn Reznick


Date: November 17, 2015

Time: 2:30AM - 5:00AM


  • Raising Capital and the IPO Process

Compared to 2014, IPO and follow-on transaction activity in 2015 has been lagging. Market volatility, triggered by international news from Greece and China for example and from uncertainty on domestic interest rate policies, may have kept some investors on the sidelines. Yet, at the same time, the fundamentals of the U.S. economy are sound.  
IPO transaction activity in the healthcare and life sciences sectors totaled 44% of all Q3 2015 IPOs signaling their continued confidence in the IPO as the right form of capital to support long development and regulatory approval processes. And when examining follow-on activity, healthcare and life sciences sectors represented a solid 48% of all middle market follow-on transactions in Q3 2015—an increase from only 18% year over year.

Join capital markets professionals from CohnReznick, Raymond James, and Mintz Levin, along with an exclusive group of life sciences executives, to discuss how today’s economic and market conditions are impacting the ability of Healthcare and Life Sciences companies to access public equity capital. 


Registration and Networking Breakfast
7:30 – 8:00 a.m.

Healthcare and Life Sciences Market Report
8:00 – 8:30 a.m.

Networking Break
8:30 – 8:45 a.m.

Panel discussion on accessing today’s public equity markets
8:45 a.m. – 9:45 a.m.

9:45 a.m. – 10 a.m.



Space is limited, so register today.

Katie Levy


Ivan K. Blumenthal is a corporate and securities attorney at Mintz. Ivan guides deals and capital markets transactions work for underwriters, companies, and investors. He represents parties in critical business transactions, including initial and follow-on public offerings, and PIPE transactions.

Mark Spelker


Partner and National Director of SEC Services, CohnReznick

Ravi Raghunathan


Partner, CohnReznick

Stuart Barich


Managing Director, Health Care Investment Banking, Raymond James

David P. Luci


President & CEO, Dipexium Pharamceuticals, Inc.

Brian Lenz


VP and CFO, Adma Biologics, Inc.